menu
    • menu
    [{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"Ionctura | AbbVie Inc | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lymphoma Academic Research Organisation \/ Ionctura | AbbVie Inc | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Lymphoma Academic Research Organisation \/ Ionctura | AbbVie Inc | Bristol Myers Squibb"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Syncona Limited","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Syncona Limited"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ INKEF Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ INKEF Capital"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Roginolisib

    Menu

    Roginolisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lymphoma Academic Research Organisation

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Lymphoma Academic Research Organisation

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ionctura | AbbVie Inc | Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

                            Details : Roginolisib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 12, 2025

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ionctura | AbbVie Inc | Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib,Docetaxel,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iOnctura Commences Randomized Phase I/II study in Non-Small Cell Lung Cancer

                            Details : IOA-244 (roginolisib) is an orally dosed small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 08, 2025

                            Lead Product(s) : Roginolisib,Docetaxel,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iOnctura Commences Randomized Phase II Study in Metastatic Uveal Melanoma

                            Details : IOA-244 (roginolisib) is an orally dosed small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of metastatic uveal melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 20, 2025

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsiv...

                            Details : Roginolisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Primary Myelofibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 20, 2025

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non S...

                            Details : Roginolisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iOnctura Reaches New Clinical Milestones in Uveal Melanoma

                            Details : IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of cutaneous melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2024

                            Lead Product(s) : Roginolisib,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

                            Details : Roginolisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uveal Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 04, 2024

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iOnctura Announces Expansion of Roginolisib Clinical Trial Program to NSCLC

                            Details : IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 09, 2024

                            Lead Product(s) : Roginolisib,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Syncona Limited

                            Deal Size : $85.9 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            iOnctura Announces €80 Million Series B Financing to Progress Pipeline Through Phase II

                            Details : The financing will be used to accelerate the development of IOA-244 (roginolisib), which is being evaluated in the mid-stage clinical trial studies for the treatment of uveal melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 20, 2024

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Syncona Limited

                            Deal Size : $85.9 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iOnctura Announces FDA Clearance of IND Application for Roginolisib, a First-in-class Allosteric Modulator of ...

                            Details : IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of metastatic uveal melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 31, 2023

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth